This not only outperforms older Factor VIII (FVIII) replacement products, but also the mean ABR rates achieved by BioMarin's late-stage gene therapy ...
https://www.google.com/url?rct=j&sa=t&url=https://scrip.pharmaintelligence.informa.com/SC146697/Sanofi-Has-One-Hemophilia-Winner-On-It-Hands--But-Fitusirans-Fate-Remains-Unclear&ct=ga&cd=CAIyGmEyNDJjNTAxZWU3OTQyNzI6Y29tOmVuOlVT&usg=AOvVaw2swSQAOyDG1knI-ihP_mbK
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.